Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

LENSAR Q3 2026 Results: Net Loss of $4.72M, Loss Widens

LENSAR, Inc. is focused on the commercialization of its ALLY Robotic Cataract Laser System while navigating the aftermath of a terminated Merger Agreement. The company continues to report operating losses and emphasizes risks related to macroeconomic conditions, regulatory clearances, and patient willingness to pay for advanced cataract procedures.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue14.114.3
Net income-4.7-3.7
EPS (diluted, $ a share)$-0.38$-0.31

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-1.3%
Operating margin-10.1%
Source

10-Q filed with the SEC, NASDAQ: LNSR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

LENSAR, Inc.: key numbers

Share price
$5.29Close, Nov 16
Market cap
$65M
Shares outstanding
12.29MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from LENSAR, Inc.

All →
7:10 AM ET 8-K
Financial Results

LENSAR Financial Results

LENSAR reported third quarter 2026 financial results, highlighted by a 17% year-over-year increase in recurring revenue to $12.6 million despite a slight 1% decline in total revenue due to seasonal factors. The company expanded its ALLY System installed base to 225 units and reported a total laser installed base of 450 systems. While the company saw a net loss of $4.7 million, Adjusted EBITDA improved to $1.7 million compared to a loss in the prior year period.

Term
Q3 2026

“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter.”

Nick Curtis, President and CEO of LENSAR

“Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue.”

Nick Curtis, President and CEO of LENSAR

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.